Company Overview
| Stock Name | Sisram Med |
|---|---|
| Stock Code | 01696 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是全球領先的能量源醫療美容器械供應商,具有自主設計、研發及生產能力,通常採用自有創新及專利技術。開發及生產用於無創及微創醫療美容治療的醫療美容器械,包括脫毛、嫩膚、靚膚、血管治療及色素性病變治療、去除紋身、暗瘡治療、脂肪消減、身體塑形及緊膚等。旗艦產品包括Soprano、Harmony、Accent及FemiLift系列,主要向醫療美容機構直銷或透過分銷商銷售。 |
| Listing Date | 2017-09-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 3079895 以色列凱撒利亞工業園區哈哈拉什街18號Ofek 15號樓 |
| Business Address (Hong Kong) | 皇后大道東1號 太古廣場三座 28樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | sisram-medical.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 8.88 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 400 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2017-09-05 to 2017-09-08 |
| Global Offering Shares | 110,000,000 shares |
| HK Public Offer Shares (Initial) | 11,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 27,500lots (Pool A13,750lots,Pool B13,750lots) |
| International Placing Shares (Initial) | 99,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 440,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 5.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 976,800,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.25B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +651% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約8.5百萬美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2014 | 2015 | 2016 | 2017-03 |
|---|---|---|---|---|
| Revenue | 101,321 | 110,406 | 118,156 | 32,647 |
| Cost of sales | -49,459 | -53,043 | -55,933 | -15,174 |
| Gross profit | 51,862 | 57,363 | 62,223 | 17,473 |
| Other income and gains, net | 281 | 450 | 719 | 971 |
| Selling and distribution expenses | -16,646 | -18,590 | -21,380 | -5,379 |
| Administrative expenses | -10,166 | -11,121 | -12,989 | -2,370 |
| Operating profit | 16,659 | 18,235 | 18,828 | 8,049 |
| Net finance costs | -7,336 | -7,308 | -6,968 | -1,711 |
| Profit before tax | 9,323 | 10,927 | 11,860 | 6,338 |
| Income tax expense | -2,618 | -2,334 | -3,359 | -1,288 |
| Profit for the year | 6,705 | 8,593 | 8,501 | 5,050 |
| Profit attributable to owners | 5,943 | 7,814 | 8,055 | 5,050 |
Balance Sheet
| Item | 2014 | 2015 | 2016 | 2017-03 |
|---|---|---|---|---|
| Cash and cash equivalents | 36,793 | 39,306 | 41,653 | 46,546 |
| Trade and bills receivables | 22,265 | 22,663 | 28,207 | 30,304 |
| Inventories | 18,431 | 21,501 | 21,955 | 24,632 |
| Total current assets | 79,594 | 85,645 | 94,968 | 105,892 |
| Total assets | 270,383 | 272,992 | 279,161 | 289,099 |
| Total current liabilities | 29,330 | 41,438 | 46,972 | 50,461 |
| Total liabilities | 245,261 | 240,447 | 238,675 | 243,216 |
| Total equity | 25,122 | 32,545 | 40,486 | 45,883 |
| Equity attributable to owners | 25,122 | 32,545 | 40,486 | 45,883 |
| Interest-bearing borrowings | 67,341 | 59,003 | 48,918 | 49,020 |
Cash Flow Statement
| Item | 2014 | 2015 | 2016 | 2017-03 |
|---|---|---|---|---|
| Net cash from operating activities | 22,807 | 15,847 | 16,013 | 4,468 |
| Net cash from investing activities | -8,503 | -2,009 | -4,182 | -1,480 |
| Net cash from financing activities | -16,413 | -12,333 | -13,052 | 425 |
| Net increase in cash | -2,109 | 1,505 | -1,221 | 3,413 |
| Depreciation of PP&E | 590 | 644 | 720 | 221 |
| Amortisation of intangible assets | 4,828 | 4,882 | 4,885 | 1,192 |
| Purchase of PP&E | -579 | -923 | -1,039 | -187 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 8.12 |
|---|---|
| First Day Open | HK$ 8.79 |
| First Day Change | -8.56% |
| First Day Volume | 38948500.0 |
| First Day Turnover | 329538000.0 |
| Use of Proceeds | 1、約18.6%,或約128.4百萬港元,預期用于擴展我們的銷售渠道及分銷網絡以及加強我們的營銷力度;
2、約18.6%,或約128.4百萬港元,用于資本開支;
3、約14.0%,或約96.3百萬港元,預期用于研究及開發活動;
4、約9.3%,或約64.2百萬港元,預期將用于償還關聯方復星實業(香港)有限公司的收購貸款;
5、約29.5%,或約202.5百萬港元,預期將用于策略性收購、設立戰略合作關系,以及其他業務發展;
6、約10.0%,或約68.9百萬港元,預期用作營運資金及一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (5)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 纽顿医学美容集团有限公司 | 29,637,888 HKD | — | 0.76% | — | 6 months | 2018-03-19 |
| 2 | 上海自贸试验区一期股权投资基金合伙企业(有限合伙) | 116,999,328 HKD | — | 2.99% | — | 6 months | 2018-03-19 |
| 3 | 升泰有限公司 | 77,998,368 HKD | — | 2.00% | — | 6 months | 2018-03-19 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉毅 | — |
| Company Secretary | 盧綺霞 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 復星醫藥透過其全資附屬公司(包括CML及能)間接持有本公司已發行股份約51.77%(假設最高發售價12.35港元)或52.96%(假設最低發售價8.88港元)。郭廣昌先生透過FIHL、FHL、復星國際等間接持有本公司已發行股份約52.96%。 |
|---|




